Women and heart disease

Basic Research in Cardiology

Volumn 93, Issue 2 SUPPL., 1998, Pages 79-84

  Maxwell, S R J ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary heart disease; Lipoproteins; Oestrogen; Women

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; LIPID;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; ESTROGEN THERAPY; FEMALE; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MENOPAUSE; PATHOPHYSIOLOGY; SECONDARY PREVENTION; SEX DIFFERENCE; VASCULAR DISEASE; VASODILATATION;

ESTROGENS; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; SEX CHARACTERISTICS;

EID: 0031767523     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s003950050225     Document Type: Article

References (33)

1. The Acute Infarction Ramipril Efficacy (AIRE) study investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821-828
2. Antiplatelet Trialists Collaboration (1994) Collaborative overview of the randomised trials of antiplatelet therapy- I: Prevention of death myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308: 81-106
3. Bar J, Tepper R, Fuchs J, Pardoe Y, Goldberger S, Ovadia J (1993) The effect of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in post-menopausal women. Obstet Gynaecol 81: 261-264 (Pubitemid 23050166)
4. Barrett-Connor E (1991) Postmenopausal oestrogen and prevention bias. Ann Int Med 115: 455-456
5. Bennett JC (1993) Inclusion of women in clinical trials - policies for population subgroups. New Eng J Med 329: 288-292 (Pubitemid 23203831)
6. Bush TL, Barret-Connor E, Cowand LD et al. (1987) Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 75: 1102-1109 (Pubitemid 17081015)
7. Col NF, Eckman MH, Karas RH et al. (1997) Patient-specific decisions about hormone replacement therapy in postmenopausal women. J Am Med Ass 277: 1140-1147 (Pubitemid 27157632)
8. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH (1987) Menopause and the risk of coronary heart disease in women. New Engl J Med 316: 1105-1110 (Pubitemid 17052498)
9. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. New Eng J Med 332: 1589-1593
10. Falkeborn M, Persson I, Adami HO et al. (1992) The risk of acute myocardial infarction after oestrogen and oestrogen-progestagen replacement. Br J Obstet Gynaecol 99: 821-828
11. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311- 322
12. Grodstein F, Stampfer MJ, Manson JE et al. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Eng J Med 335: 453-461 (Pubitemid 26269944)
13. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA (1988) Postmenopausal use of oestrogen and occlusion of coronary arteries. Am Heart J 115: 954-963
14. Gruetta V, Cannon O (1996) Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 93: 1928-1937
15. Gruetta V, Panza JA, Waclawiw MA, Cannon RO (1995) Effect of combined 17-b oestradiol and vitamin E on low-density lipoprotein oxidation in post-menopausal women. Am J Cardiol 75: 1274-1276
16. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs D, Frantz ID (1980) Lipoprotein cholesterol distributions in selected North American populations: The Lipid Research Clinics Program prevalence Study. Circulation 60: 302-315 (Pubitemid 10214988)
17. Isles CG, Hole DJ, Hawthorne VM, Lever AF (1992) Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: Comparison with men. Lancet 339: 702-706
18. ISIS-1 (First International Study of Infarct Survival) Collaborative Group (1986) Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet ii: 57-66
19. Keaney JF Jr, Shwaery GT, Xu A et al. (1994) 17b-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolaemic swine. Circulation 89: 2251-2259
20. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P (1996) Prior to use of oestrogen replacement therapy are users healthier than non-users? Am J Epidemiol 143: 971-978 (Pubitemid 26140324)
21. McFarland KF, Boniface FE, Hornung CA, Earnhardt W, Humphries J (1989) Risk factors and non-contraceptive estrogen use in women and without coronary artery disease. Am Heart J 117: 1209-1214 (Pubitemid 19150748)
22. Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ (1994) Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein (a). J Lab Clin Med 123: 837-841
23. van der Mooren MJ, de Graaf J, Demacker PNM, de Haan AFJ, Rolland R (1994) Changes in the low-density lipoprotein profile during 17b-estradiol-dihydrogesterone therapy in post-menopausal women. Metabolism 43: 799-802 (Pubitemid 24213294)
24. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P (1993) Beneficial effects of oestrogen on exercise-induced myocardial ischaemia in women with coronary heart disease. Lancet 342: 133-136 (Pubitemid 23200438)
25. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
26. Stampfer M, Willett W, Colditz G, Rosner B, Speizer F, Hennekens C (1985) A prospective study of post-menopausal estrogen therapy and coronary heart disease. New Eng J Med 313: 1044-1049 (Pubitemid 16243331)
27. Stampfer MJ, Colditz GA, Willett WC et al. (1991) Postmenopausal estrogen therapy and cardiovascular disease: ten year follow- up from the nurses health study. New Eng J Med 325: 756-762
28. Stampfer MJ, Colditz GA (1991) Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence. Prevent Med 20: 47-63
29. Sullivan J, Vander Zwang R, Lemp GF et al. (1988) Postmenopausal estrogen use and coronary atherosclerosis. Ann Int Med 108: 358-363
30. Sullivan JM, Zwaag RV, Hughes JP et al. (1990) Oestrogen replacement and coronary artery disease. Effect on survival in post-menopausal women. Arch Int Med 150: 2557-2562
31. Willett WC, Green A, Stampfer MJ et al. (1987) Relative and absolute risk of coronary heart disease among women who smoke cigarettes. New Eng J Med 317: 1303-1309 (Pubitemid 17153011)
32. Williams JK, Adams MR, Klopfenstein HS (1990) Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 81: 1680-1687 (Pubitemid 20158307)
33. The Writing Group for the PEPI Trial (1995) Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in Postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Am Med Ass 273: 199-208